Literature DB >> 17912954

Hepatocyte transplantation for glycogen storage disease type Ib.

Kwang-Woong Lee1, Ji-Hyun Lee, Sung Wook Shin, Sung Joo Kim, Jae Won Joh, Doo-Hoon Lee, Jong-Won Kim, Hwa-Young Park, Soo-Youn Lee, Hwan Hyo Lee, Jin Wan Park, Shi-Yeon Kim, Hee-Hoon Yoon, Doo-Hee Jung, Yon Ho Choe, Suk-Koo Lee.   

Abstract

Glycogen storage disease type I (GSD-I) is a group of autosomal recessive disorders with an incidence of 1 in 100,000. The two major subtypes are GSD-Ia, caused by a deficiency of glucose-6-phosphatase (G6Pase), and GSD-Ib, caused by a deficiency of glucose-6-phosphate transporter (G6PT). We report that a substantial improvement was achieved following several infusions of hepatocytes in a patient with GSD-Ib. Hepatocytes were isolated from the unused cadaveric whole livers of two donors. At the first transplantation, approximately 2 x 10(9) cells (2% of the estimated recipient's total hepatocytes) were infused. Seven days later 1 x 10(9) (1% of liver mass) cryopreserved hepatocytes from the same donor were infused, and an additional 3 x 10(9) (3% of liver mass) cells from the second donor were infused 1 month after the second transplantation. After the hepatocyte transplantation, the patient showed no hypoglycemic symptoms despite the discontinuation of cornstarch meals. Liver biopsies on posttransplantation days 20 and 250 showed a normal level of glucose-6-phosphatase activity in presolubilization assay that was very low before transplantation. This was the first and successful clinical hepatocyte transplantation in Korea. In this study, hepatocyte transplantation allowed a normal diet in a patient with GSD-Ib, with substantial improvement in their quality of life. Hepatocyte transplantation might be an alternative to liver transplantation and dietary therapy in GSD-Ib.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912954     DOI: 10.3727/000000007783465019

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  27 in total

1.  Improvement of Infusion Process in Cell Transplantation: Effect of Shear Stress on Hepatocyte Viability Under Horizontal and Vertical Syringe Orientation.

Authors:  Sandi Sufiandi; Hiromichi Obara; Shin Enosawa; Huai-Che Hsu; Naoto Matsuno; Hiroshi Mizunuma
Journal:  Cell Med       Date:  2014-12-12

2.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

3.  Hepatocyte transplantation.

Authors:  Ragai R Mitry; Robin D Hughes; Anil Dhawan
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 4.  Human hepatocyte transplantation: current experience and future challenges.

Authors:  Anil Dhawan; Juliana Puppi; Robin D Hughes; Ragai R Mitry
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

Review 5.  Cell-based liver therapies: past, present and future.

Authors:  Valeria Iansante; Anil Chandrashekran; Anil Dhawan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

6.  Hepatocyte Transplantation in Special Populations: Clinical Use in Children.

Authors:  Zahida Khan; Stephen C Strom
Journal:  Methods Mol Biol       Date:  2017

7.  Gallbladder epithelial cells that engraft in mouse liver can differentiate into hepatocyte-like cells.

Authors:  Sum P Lee; Christopher E Savard; Rahul Kuver
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

8.  Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD).

Authors:  Kristen J Skvorak; Elizabeth J Hager; Erland Arning; Teodoro Bottiglieri; Harbhajan S Paul; Stephen C Strom; Gregg E Homanics; Qin Sun; Erwin E W Jansen; Cornelis Jakobs; William J Zinnanti; K Michael Gibson
Journal:  Biochim Biophys Acta       Date:  2009-08-19

9.  Hepatocyte transplantation improves phenotype and extends survival in a murine model of intermediate maple syrup urine disease.

Authors:  Kristen J Skvorak; Harbhajan S Paul; Kenneth Dorko; Fabio Marongiu; Ewa Ellis; Donald Chace; Carolyn Ferguson; K Michael Gibson; Gregg E Homanics; Stephen C Strom
Journal:  Mol Ther       Date:  2009-05-12       Impact factor: 11.454

Review 10.  The SLC37 family of phosphate-linked sugar phosphate antiporters.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.